Search Results

Your search for Kathleen Moore, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2023 ASCO Annual Meeting

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Kathleen N. Moore, MD, of the Stephenson Oklahoma Cancer Center at the University of Oklahoma, discuss phase III results from the MIRASOL trial, which showed that mirvetuximab soravtansine-gynx prolonged overall survival vs investigator’s...

gynecologic cancers

By The ASCO Post Staff / 2018 ASCO Annual Meeting

Kathleen N. Moore, MD, on Ovarian Cancer: Results From the QUADRA Study

Kathleen N. Moore, MD, of the University of Oklahoma Health Sciences Center, discusses phase II study findings on niraparib in patients with relapsed ovarian cancer who have received three or more prior chemotherapy regimens (Abstract 5514).

Apr

Today In Oncology

Search Results

Your search for Kathleen Moore, MD matches 2 pages

Bobbie J. Rimel, MD, and Kathleen N. Moore, MD, on Ovarian Cancer: New Findings on Mirvetuximab Soravtansine vs Chemotherapy

Kathleen N. Moore, MD, on Ovarian Cancer: Results From the QUADRA Study

Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Cervical Cancer

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

Cabozantinib in Metastatic Pheochromocytomas or Paragangliomas

Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy

Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors